Our studies focused on a limited panel of PDX cell lines and further investigation into the effects of BET inhibition and FGFR1-mediated resistance in a larger panel of GBM cell lines is warranted given the heterogeneity of GBM. The gene discussed is FGFR1; the disease is glioblastoma.